157 related articles for article (PubMed ID: 29449085)
1. The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.
Roex MCJ; Hageman L; Heemskerk MT; Veld SAJ; van Liempt E; Kester MGD; Germeroth L; Stemberger C; Falkenburg JHF; Jedema I
Cytotherapy; 2018 Apr; 20(4):543-555. PubMed ID: 29449085
[TBL] [Abstract][Full Text] [Related]
2. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
3. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
Odendahl M; Grigoleit GU; Bönig H; Neuenhahn M; Albrecht J; Anderl F; Germeroth L; Schmitz M; Bornhäuser M; Einsele H; Seifried E; Busch DH; Tonn T
Cytotherapy; 2014 Sep; 16(9):1245-56. PubMed ID: 25108651
[TBL] [Abstract][Full Text] [Related]
4. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
Müller N; Landwehr K; Langeveld K; Stenzel J; Pouwels W; van der Hoorn MAWG; Seifried E; Bonig H
Cytotherapy; 2018 Apr; 20(4):532-542. PubMed ID: 29500069
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
6. Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy.
Faist B; Schlott F; Stemberger C; Dennehy KM; Krackhardt A; Verbeek M; Grigoleit GU; Schiemann M; Hoffmann D; Dick A; Martin K; Hildebrandt M; Busch DH; Neuenhahn M
PLoS One; 2019; 14(9):e0223258. PubMed ID: 31568490
[TBL] [Abstract][Full Text] [Related]
7. Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8
Ciáurriz M; Beloki L; Bandrés E; Mansilla C; Zabalza A; Pérez-Valderrama E; Lachén M; Ibáñez B; Olavarría E; Ramírez N
Cytometry B Clin Cytom; 2017 Mar; 92(2):153-160. PubMed ID: 26918565
[TBL] [Abstract][Full Text] [Related]
8. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
9. A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.
van Loenen MM; de Boer R; van Liempt E; Meij P; Jedema I; Falkenburg JH; Heemskerk MH
Haematologica; 2014 Apr; 99(4):759-68. PubMed ID: 24334296
[TBL] [Abstract][Full Text] [Related]
10. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
11. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
12. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.
Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R
J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047
[TBL] [Abstract][Full Text] [Related]
13. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer.
Bacher P; Jochheim-Richter A; Mockel-Tenbrink N; Kniemeyer O; Wingenfeld E; Alex R; Ortigao A; Karpova D; Lehrnbecher T; Ullmann AJ; Hamprecht A; Cornely O; Brakhage AA; Assenmacher M; Bonig H; Scheffold A
Cytotherapy; 2015 Oct; 17(10):1396-405. PubMed ID: 26188965
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.
Beloki L; Ciaurriz M; Mansilla C; Zabalza A; Perez-Valderrama E; Samuel ER; Lowdell MW; Ramirez N; Olavarria E
J Transl Med; 2015 May; 13():165. PubMed ID: 25990023
[TBL] [Abstract][Full Text] [Related]
15. The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8+ T-cells by multimer technology in Adoptive Immunotherapy.
Beloki L; Ciáurriz M; Mansilla C; Bandrés E; Rodríguez-Calvillo M; Ramírez N; Olavarría E
J Immunol Methods; 2013 Oct; 396(1-2):168-72. PubMed ID: 23933324
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
Zandvliet ML; van Liempt E; Jedema I; Kruithof S; Kester MG; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2011 Apr; 34(3):307-19. PubMed ID: 21389867
[TBL] [Abstract][Full Text] [Related]
17. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
18. Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells.
Jedema I; van de Meent M; Pots J; Kester MG; van der Beek MT; Falkenburg JH
Haematologica; 2011 Aug; 96(8):1204-12. PubMed ID: 21546501
[TBL] [Abstract][Full Text] [Related]
19. Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System.
Kumaresan P; Figliola M; Moyes JS; Huls MH; Tewari P; Shpall EJ; Champlin R; Cooper LJ
J Vis Exp; 2015 Oct; (104):. PubMed ID: 26484782
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
